Abstract
Natural killer (NK) cells represent a potent subset of lymphocytes for targeting and lysing tumor cells. In contrast to T lymphocytes, they do not need to be preactivated in vitro because they constitutively express cytolytic functions against a number of different targets (1,2). Their inherent cytolytic activity can be stimulated via the FcγIIIA receptor (CD16), which is expressed on the surface of NK cells, macrophages, and activated monocytes (3,4). Bispecific antibodies binding to both CD16 and a tumorassociated antigen are therefore of great interest as potential reagents for cancer immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gudelj L., Deniz G., Rukavina D., Johnson P. M., and Christmas S. E. (1996). Expression of functional molecules by human CD3-decidual granular leucocyte clones. Immunology 87, 609–615.
Herberman R. B. and Ortaldo J. R. (1981). Natural killer cells: the role in defense against disease. Science 214, 24–30.
Fanger M. W., Morganelli P. M., and Guyre P. M. (1993). Use of bispecific antibodies in the therapy of tumors. Cancer Treat. Res. 68, 181–194.
Moretta A., Tambussi G., Ciccone E., Pende D., Melioli G., and Moretta L. (1989). CD16 surface molecules regulate ths cytolytic function of CD3-CD16+ human natural killer cells. Int. J. Cancer 44, 727–730.
Hombach A., Jung W., Renner C., Sahin U., Schmits R., Wolf J., et al. (1993). A CD16/ CD30 bispecific monoclonal antibody induces lysis of Hodgkin’s cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer 55, 830–836.
Stein H., Mason D. Y., Gerdes J., O©onnor N., Wainscoat J., Pallesen G., et al. (1985). The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66, 848–858.
Hartmann F., Renner C., Jung W., Deisting C., Juwana M., Eichentopf B., et al. (1997). Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 89, 2042–2047.
Hartmann F., Renner C., Jung W., and Pfreundschuh M. (1998). Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin’s disease. Leuk. Lymphoma 31, 385–392.
Renner C., Hartmann F., Jung W., Deisting C., Juwana M., and Pfreundschuh M. (2000). Initiation of humoral and cellular immune responses in patients with refractory Hodgkin’s disease by treatment with an anti-CD16/CD30 bispecific antibody. Cancer Immunol. Immunother. 49, 173–180.
Atwell J. L., Pearce L. A., Lah M., Gruen L. C., Kortt A., and Hudson P. (1996). Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neurominidase. Mol. Immunol. 33, 1301–1312.
Holliger P., Prospero T., and Winter G. (1993). “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448.
Holliger P., Brissinck J., Williams R. L., Thielmans K., and Winter G. (1996). Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Prot. Eng. 9, 299–305.
Zhu Z., Zapata G., Shalaby R., Snedecor B., Chen H., and Carter P. (1996). High-Level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14, 192–196.
Perisic O., Webb P. A., Holliger P., Winter G., and Williams R. L. (1994). Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217–1226.
Matzinger P. (1991). The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145, 185–192.
von Kalle C., Wolf J., Becker A., Sckaer A., Munck M., Engert A., et al. (1992). Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int. J. Cancer 52, 887–891.
Kipriyanov S. M., Moldenhauer G., Srauss G., and Little M. (1998). Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77, 763–772.
Bradford M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
English D. and Andersen B. R. (1974). Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J. Immunol. Methods 5, 249–252.
Bosma G. C., Custer R. P., and Bosma M. J. (1983). A severe combined immunodeficiencymutation in the mouse. Nature 301, 527–530.
Schuler W., Weiler I. J., Schuler A., Phillips R. A., Rosenberg N., Mak T. W., et al. (1986). Rearrangement of antigen receptor genes defective in mice with severe combined immune deficiency. Cell 46, 963–972.
Kipriyanov S. M., Moldenhauer G., and Little M. (1997). High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol. Methods 200, 69–77.
Sharma S. K., Evans D. B., Vosters A. F., Chattopadhyay D., Hoogerheide J. G., and Campbell C. M. (1992). Immobilized metal affinity chromatography of bacterially expressed proteins engineered to contain an alternating-histidine domain, in Methods: A Companion to Methods in Enzymology (Arnold F., ed.) Academic Press NY, pp. 57–67.
Duebel S., Dübel S., Breitling F., et al. (1994). Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J. Mol. Methods 175, 89–95.
Arndt M., Krauss J., Kipriyanov S. M., et al. (1999). A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 2562–2568.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Arndt, M., Krauss, J. (2003). Bispecific Diabodies for Cancer Therapy. In: Welschof, M., Krauss, J. (eds) Recombinant Antibodies for Cancer Therapy. Methods in Molecular Biology™, vol 207. Humana Press. https://doi.org/10.1385/1-59259-334-8:305
Download citation
DOI: https://doi.org/10.1385/1-59259-334-8:305
Publisher Name: Humana Press
Print ISBN: 978-0-89603-918-6
Online ISBN: 978-1-59259-334-7
eBook Packages: Springer Protocols